TARA-002 clinical trials
TARA-002 is named as an intervention in 3 current clinical trials in our USA, Canada, Brazil, Japan and Taiwan registers. 3 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Protara Therapeutics. The most-studied condition is Non-muscle Invasive Bladder Cancer.
Patient leaflets for TARA-002
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of TARA-002
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
NCT07480356 · Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
|
Phase 3 | Recruiting | Protara Therapeutics | USA |
|
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
NCT05871970 · Lymphatic Malformation
|
Phase 2 | Recruiting | Protara Therapeutics | USA |
|
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
NCT05951179 · Non-muscle Invasive Bladder Cancer
|
Phase 2 | Recruiting | Protara Therapeutics | USA, Canada, Brazil, Japan, Taiwan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with TARA-002
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Protara Therapeutics | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 3 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Brazil | 1 | 1 |
| Clinical trials in Japan | 1 | 1 |
| Clinical trials in Taiwan | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about TARA-002 trials
How many clinical trials are testing TARA-002?
3 current trials in our USA, Canada, Brazil, Japan and Taiwan registers name TARA-002 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are TARA-002 trials recruiting patients?
Yes. 3 of the 3 trials are recruiting: 3 with sites in USA, 1 with sites in Canada, 1 with sites in Brazil, 1 with sites in Japan and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors TARA-002 clinical trials?
The lead sponsor is Protara Therapeutics. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how TARA-002 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how TARA-002 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists TARA-002 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.